New drugs effective at treating hepatitis C, but at a price

New drugs effective at treating hepatitis C, but at a price
PROVIDENCE, R.I. (AP) – Rhode Island Department of Corrections officials say that new drugs are effective at treating hepatitis C. But their steep price has made it difficult to decide when to treat inmates and how to pay for their care. The Providence …
Read more here.

Gilead Sciences: Why Nomura Sees Upside in Hepatitis C
Nomura's M. Ian Somaiya and team explain think Gilead Sciences' (GILD) revenues from its hepatitis-c treatments will surprise folks. They explain why: Gilead Sciences. Our analysis of IMS scrip data points to upside in Gilead's HCV franchise, with 1Q …
Read more here.

Hepatitis C Will Share Spotlight This Year at Liver Congress
Hepatitis C will again be a hot topic at this year's European Association for the Study of the Liver (EASL) International Liver Congress, but other subjects, such as nonalcoholic fatty liver disease, hepatocellular carcinoma, and noninvasive liver …
Read more here.

The Best Stock to Invest in Hep C
The market for hepatitis C treatment is among the most lucrative for drugmakers, but it's also one of the most dynamically changing markets. Only 10 years ago, patients were treated with side effect-laden cocktails of drugs that offered coin-flip cure …
Read more here.

Cheap allergy drug may be effective for hepatitis C
Preliminary lab research suggests a hay fever drug that costs about 50 cents a pill has the potential to treat hepatitis C, a stubborn disease that has spawned drugs that sell for $ 1,000 a dose. It's too early to know if the antihistamine …
Read more here.

Gilead Sciences Sparks Analyst Dispute Over Hep C Forecasts
In February, Gilead caused a minor investor freak out when management disclosed that the company's 2015 hepatitis C drug gross-to-net adjustment was going to be about 46%, or more than double the 22% in 2014. Gross to net measures the level of …
Read more here.

Gilead's 00 Pill Is Hard for States to Swallow
State Medicaid programs spent $ 1.33 billion on hepatitis C therapies through the third quarter of last year, or nearly as much as the states spent in the previous three years combined, a Wall Street Journal analysis of federal data shows. The growth …
Read more here.


Leave a Reply